beta
Trial Radar AI
Clinical Trial NCT07498686 for RT-QuIC is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease 458 Biomarker-Driven Novel Treatment

Recruiting
Clinical Trial NCT07498686 is an observational study for RT-QuIC that is recruiting. It started on 1 May 2023 with plans to enroll 458 participants. Led by Xuanwu Hospital, Beijing, it is expected to complete by 23 December 2026. The latest data from ClinicalTrials.gov was last updated on 27 March 2026.
Brief Summary
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lewy neurites, neurons,...Show More
Official Title

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease

Conditions
RT-QuIC
Other Study IDs
  • 115
NCT ID Number
Start Date (Actual)
2023-05-01
Last Update Posted
2026-03-27
Completion Date (Estimated)
2026-12-23
Enrollment (Estimated)
458
Study Type
Observational
Status
Recruiting
Keywords
PD, MSA, PSP, Neurodegeneration disease, alpha-synuclein
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Control
Control: healthy subjects,
N/A
PD
parkinson's disease patients
N/A
MSA
MSA: multiple system atrophy
N/A
PSP
progressive supranuclear palsy
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
slope
slope of all Fluorescence value
From enrollment to the end of treatment at 21 weeks
MAX
Maximum fluorescence value
From enrollment to the end of treatment at 21 weeks
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes

- Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn & Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.

  • Patients with Parkinson's syndrome but not primary PD, patients with brain surgery/deep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.
Xuanwu Hospital, Beijing logoXuanwu Hospital, Beijing
Study Central Contact
Contact: Weiwei YANG, Ph.D., +86 010-83198271, [email protected]
2 Study Locations in 1 Countries

Beijing Municipality

Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Completed
Xuanwu Hospital, Beijing, Beijing Municipality, 100053, China
Weiwei YANG, Contact, +86 010-83198271, [email protected]
Recruiting